Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7854]

For resistant breast cancers, two drugs may be better than one

For resistant breast cancers, two drugs may be better than one

Bowel cancer: Researchers find possible cause for chemoresistance

Bowel cancer: Researchers find possible cause for chemoresistance

Engineered white blood cells eliminate cancer

Engineered white blood cells eliminate cancer

EHA 2023: Selinexor subgroup data from the BOSTON trial highlights its clinical potential in R/R Multiple Myeloma

EHA 2023: Selinexor subgroup data from the BOSTON trial highlights its clinical potential in R/R Multiple Myeloma

ASCO 2023: Ciltacabtagene autoleucel reduces risk of disease progression by 74% in multiple myeloma after lenalidomide stops working

ASCO 2023: Ciltacabtagene autoleucel reduces risk of disease progression by 74% in multiple myeloma after...

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced...

ASCO 2023: Phase 3 trial demonstrates one-year PFS in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

ASCO 2023: Phase 3 trial demonstrates one-year PFS in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma...

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO 2023: Results of SWOG S1929 trial show small-cell lung cancer patients with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade

ASCO 2023: Results of SWOG S1929 trial show small-cell lung cancer patients with SLFN11 expression can benefit...

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced ovarian cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced...

More from ecancer